Glen Eagle Advisors, LLC Biomea Fusion, Inc. Transaction History
Glen Eagle Advisors, LLC
- $527 Billion
- Q1 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 250 shares of BMEA stock, worth $1,362. This represents 0.0% of its overall portfolio holdings.
Number of Shares
250Holding current value
$1,362% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BMEA
# of Institutions
123Shares Held
25.8MCall Options Held
2.56MPut Options Held
879K-
State Street Corp Boston, MA4.49MShares$24.4 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.57MShares$19.5 Million3.07% of portfolio
-
Laurion Capital Management LP New York, NY2.72MShares$14.8 Million0.36% of portfolio
-
Baker Bros. Advisors LP New York, NY2.11MShares$11.5 Million0.4% of portfolio
-
Black Rock Inc. New York, NY1.97MShares$10.8 Million0.0% of portfolio
About Biomea Fusion, Inc.
- Ticker BMEA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,290,600
- Market Cap $160M
- Description
- Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...